Pascale Richetta - UCB SA Insider

UCB SA -- USA Stock  

USD 35.89  0.81  2.31%

Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee

Ms. Pascale Richetta was Executive Vice President, Bone Patient Value Unit Head and Member of the Executive Committee of UCB S.A. since February 1, 2016. She has over 20 years of experience in the pharma and biotech industry. She has acquired commercial experience managing both traditional pharmaceuticals and complex biologics. Her experience and knowledge of markets around the world is key to helping UCB prepare for future product launches. Trained as a medical doctor, Pascale Richetta leads UCBs Bone Patient Value Unit. One of her main missions is to take UCBs investigational osteoporosis drug through the next steps in its development and prepare for its potential launch upon approval. Key positions Prior to UCB, Pascale held the following positions 2013 Present AbbVie Vice President, Western Europe and Canada In charge of a multibillion specialty care portfolio including key biologic products Covering 19 affiliates and over 3000 staff 2004 2013 Abbott Vice President, Western Europe and Canada 1994 2004 GSK Operations Director in France and Europe in charge of the Central Nervous System franchise 19901994 Ipsen Marketing Manager, France 19871990 Product Manager, France. Education 1985 Universite de Poitiers, France M.D. Prior trade association engagement EFPIA Vice Chair of the Executive Committee, member of the Board EBE Member of the Board Europa BIO Member of the Board.
Age: 57  President Since 2016      
32 2 559 99 99  http://www.ucb-group.com

Management Efficiency

The company has return on total asset (ROA) of 5.76 % which means that it generated profit of $5.76 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.02 % meaning that it generated $13.02 on every $100 dollars invested by stockholders.
The company has accumulated 1.9 B in total debt with debt to equity ratio (D/E) of 28.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. UCB SA has Current Ratio of 1.09 suggesting that it may not have the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA (UCBJY) is traded on OTC Market in USA. It is located in Allée de la Recherche, Brussels, and employs 7,643 people.

Did you try this?

Run Aroon Oscillator Now
   

Aroon Oscillator

Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Hide  View All  Next  Launch Aroon Oscillator
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add UCB SA to your portfolio

Top Management

UCB SA Leadership Team
Pascale Richetta, President
Detlef Thielgen, CFO
Kay Davies, Director
Anna Richo, EVP
Gerhard Mayr, Chairman
Cyril Janssen, Director
Cedric Rijckevorsel, Director, CFA
JeanChristophe Tellier, Chairman
Arnoud Calesberg, Director
Mark McDade, COO
Xavier Michel, President
Bharat Tewarie, President, MBA
Roch Doliveux, Chairman, Ph.D
Norman Ornstein, Director
Jeff Wren, President
JeanPierre Kinet, Director, Ph.D
Antje Witte, VP
Alice Dautry, Director
Harriet Edelman, Director, MBA
Ulf Wiinberg, Director
Thomas McKillop, Director, Ph.D
Charl Zyl, President
Fabrice Enderlin, President
Pierre Gurdjian, Director
Ismail Kola, EVP, Ph.D
Emmanuel Caeymaex, President
Evelyn Bergendal, Executive
Iris LoewFriedrich, President, Ph.D
CharlesAntoine Janssen, Director
Albrecht Graeve, Director

Stock Performance

UCB SA Performance Indicators